Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Mirum Pharmaceuticals, Inc. - common stock
(NQ:
MIRM
)
94.29
-1.74 (-1.81%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mirum Pharmaceuticals, Inc. - common stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Expert Ratings for Mirum Pharmaceuticals
↗
May 23, 2022
Within the last quarter, Mirum Pharmaceuticals (NASDAQ:MIRM) has observed the following analyst ratings:
Via
Benzinga
Mirum Pharma Acquires Its Licensing Partner In Cash and Stock
↗
May 23, 2022
Via
Benzinga
Mirum Pharmaceuticals Acquires Satiogen Pharmaceuticals
May 23, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
May 18, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Recap: Mirum Pharmaceuticals Q1 Earnings
↗
May 05, 2022
Mirum Pharmaceuticals (NASDAQ:MIRM) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
83 Biggest Movers From Yesterday
↗
May 06, 2022
Gainers Hudson Technologies, Inc. (NASDAQ: HDSN) shares jumped 26.9% to close at $9.06 on Thursday after the company reported better-than-expected Q1 EPS and sales results.
Via
Benzinga
57 Stocks Moving In Thursday's Mid-Day Session
↗
May 05, 2022
Gainers
Via
Benzinga
Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
May 05, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
A Preview Of Mirum Pharmaceuticals's Earnings
↗
May 04, 2022
Mirum Pharmaceuticals (NASDAQ:MIRM) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Mirum...
Via
Benzinga
Mirum Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 5, 2022
May 02, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 08, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute
↗
March 09, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus AbbVie Settles With Alvotech On Humira Biosimilar Patent Dispute AbbVie, Inc...
Via
Benzinga
Stocks That Hit 52-Week Highs On Thursday
↗
April 07, 2022
On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high...
Via
Benzinga
Earnings Scheduled For March 9, 2022
↗
March 09, 2022
Companies Reporting Before The Bell • REV Group (NYSE:REVG) is expected to report quarterly earnings at $0.11 per share on revenue of $529.44 million. • Express (...
Via
Benzinga
Earnings Preview For Mirum Pharmaceuticals
↗
March 08, 2022
Mirum Pharmaceuticals (NASDAQ:MIRM) is set to give its latest quarterly earnings report on Wednesday, 2022-03-09. Here's what investors need to know before the announcement....
Via
Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
↗
March 06, 2022
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (...
Via
Benzinga
Week In Review: Huadong Pharma Enters $662 Million Deal For Two Kiniksa Anti-Inflammatory Drugs
↗
February 26, 2022
Huadong Pharma announced a $662 million agreement to develop two Kiniksa Pharma anti-inflammatory drug candidates in southeast Asia (ex-Japan). Huadong will pay $22 million and be responsible for up to...
Via
Talk Markets
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 10, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Present at SVB Leerink 11th Annual Global Healthcare Conference
February 09, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones
January 11, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
January 04, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Added to NASDAQ Biotechnology Index
December 15, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
LIVMARLI (maralixibat) Presentations Show Improvements in Quality of Life Measures in Alagille Syndrome and PFIC2 at NASPGHAN Annual Meeting 2021
December 13, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Present LIVMARLI™ (maralixibat) Analyses at NASPGHAN 2021 Annual Meeting
December 06, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
November 22, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher
November 17, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
November 15, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Six-Year Natural History Comparison with Mirum’s LIVMARLI (maralixibat) Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with Alagille Syndrome
November 15, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
